The following is the top 100 pharmaceutical industry rankings in 2009, which can be used as a basis to analyze the regional pharmaceutical industry situation
Ranking company names
1 Yangzijiang Pharmaceutical Group Co., Ltd. Companies (including: Yangtze River Pharmaceutical Group Shanghai Haini Pharmaceutical Co., Ltd.)
2Harbin Pharmaceutical Group Co., Ltd. (including: Harbin Pharmaceutical Group Sanjing Pharmaceutical Co., Ltd.)
3 Correction Pharmaceutical Group
4 CSPC Pharmaceutical Group Co., Ltd. (including: CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd., Shijiazhuang Pharmaceutical Group Ouyi Pharmaceutical Co., Ltd., CSPC Yinhu Pharmaceutical Co., Ltd.)
5 Tianjin Tasly Group Co., Ltd. (including: Tianjin Tasly Pharmaceutical Co., Ltd., Jiangsu Tasly Diyi Pharmaceutical Co., Ltd., Tianjin Tasly Modern Traditional Chinese Medicine Resources Co., Ltd.)
6 Weigao Group Co., Ltd.
7 North China Pharmaceutical Group Co., Ltd. (including: North China Pharmaceutical Co., Ltd., North China Pharmaceutical Group Preparations Co., Ltd.)
8 Northeast Pharmaceutical Group Co., Ltd.
9 Taiji Group Co., Ltd. (including: Taiji Group Chongqing Fuling Pharmaceutical Factory Co., Ltd., Taiji Group Mianyang Pharmaceutical Co., Ltd., Southwest Pharmaceutical Co., Ltd., Taiji Group Chongqing Tongjunge Pharmaceutical Factory Co., Ltd., Taiji Group Chongqing Traditional Chinese Medicine Factory 2, Taiji Group Sichuan Taiji Pharmaceutical Co., Ltd., Taiji Group Zhejiang Dongfang Pharmaceutical Co., Ltd., Taiji Group Sichuan Tiancheng Pharmaceutical Co., Ltd.)
10 Beijing Shuanghe Pharmaceutical Co., Ltd. (including: Anhui Shuanghe Pharmaceutical Co., Ltd., Beijing Wanhui Shuanghe Pharmaceutical Co., Ltd., Xi'an Jingxi Shuanghe Pharmaceutical Co., Ltd., Shanxi Jinxin Shuanghe Pharmaceutical Co., Ltd., Beijing Shuanghe Modern Pharmaceutical Technology Co., Ltd.)
11 China Resources Sanjiu Pharmaceutical Co., Ltd. (including: Shenzhen Jiuxin Pharmaceutical Co., Ltd.)
12 Xi'an Janssen Pharmaceutical Co., Ltd.
13 Qilu Pharmaceutical Co., Ltd. (including: Qilu Pharmaceutical (Hainan) Co., Ltd., Qilu Tianhe Huishi Pharmaceutical Co., Ltd., Qilu Anti Pharmaceutical Co., Ltd.)
14 Zhejiang Pharmaceutical Co., Ltd. (including: Zhejiang Pharmaceutical Co., Ltd. Xinchang Pharmaceutical Factory, Zhejiang Pharmaceutical Co., Ltd. Vitamin Factory)
15 Zhuhai United Laboratories Co., Ltd.
16 Sichuan Kelun Pharmaceutical Co., Ltd. (including: Hunan Kelun Pharmaceutical Co., Ltd., Jiangxi Kelun Pharmaceutical Co., Ltd., Hunan Zhongnan Kelun Pharmaceutical Co., Ltd., Heilongjiang Kelun Pharmaceutical Co., Ltd., Shandong Kelun Pharmaceutical Co., Ltd., Hubei Topeng Pharmaceutical Co., Ltd., Kunming Nanjiang Pharmaceutical Co., Ltd., Liaoning Minkang Pharmaceutical Co., Ltd. , Sichuan Pearl Pharmaceutical Co., Ltd., Sichuan Xinyuan Pharmaceutical Co., Ltd., Heilongjiang Kelun Pharmaceutical Packaging Co., Ltd., Sichuan Kelun Pharmaceutical Packaging Co., Ltd., Jilin Kelun Cornell Pharmaceutical Co., Ltd., Sichuan Kelun Pharmaceutical Co., Ltd. Guang'an Branch Company, Renshou Branch of Sichuan Kelun Pharmaceutical Co., Ltd.)
17 Zhejiang Hisun Pharmaceutical Co., Ltd.
18 Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (including : Chongqing Yaoyou Pharmaceutical Co., Ltd., Shanghai Zhaohui Pharmaceutical Co., Ltd., Chongqing Kailin Pharmaceutical Co., Ltd., Guilin Nanyang Pharmaceutical Co., Ltd., Shanghai Clone Biotech Co., Ltd.)
19 Ruiyang Pharmaceutical Co., Ltd.
20 Furen Pharmaceutical Group Co., Ltd. (including: Kaifeng (Pharmaceutical) Group Co., Ltd., Henan Furentang Pharmaceutical Co., Ltd., Henan Furen Huaiqingtang Pharmaceutical Co., Ltd., Henan Yunyuan Pharmaceutical Co., Ltd. )
21 Shandong Medicinal Glass Co., Ltd.
22 Pfizer Pharmaceutical Co., Ltd.
23 Zhejiang Xinhecheng Co., Ltd.
24 Lunan Pharmaceutical Group Co., Ltd. (including: Lunan Better Pharmaceutical Co., Ltd., Shandong New Era Pharmaceutical Co., Ltd., Lunan Houpu Pharmaceutical Co., Ltd.)
25 Sanofi-Aventis ( Hangzhou) Pharmaceutical Co., Ltd.
26 Renhe (Group) Development Co., Ltd.
27 Livzon Pharmaceutical Group Co., Ltd. (
Including: Livzon Group Livzon Pharmaceutical Factory, Livzon Group Zhuhai Free Trade Zone Livzon Synthetic Pharmaceutical Co., Ltd., Shanghai Livzon Pharmaceutical Co., Ltd., Livzon Group Fuzhou Fuxing Pharmaceutical Co., Ltd., Livzon Group Limin Pharmaceutical Factory, Livzon Group Xinbeijiang Pharmaceutical Co., Ltd., Livzon Group Zhuhai Free Trade Zone Lida Pharmaceutical Co., Ltd.)
28 Shandong Xinhua Pharmaceutical Group Co., Ltd.
29 Hangzhou MSD Pharmaceutical Co., Ltd.
30 Beijing Novartis Pharmaceutical Co., Ltd.
31 Henan Tianfang Pharmaceutical Co., Ltd.
32 China Resources Dong-E E-Jiao Co., Ltd.
33 Zhejiang Shenghua Bye Gram Biotechnology Co., Ltd.
34 Simcere Pharmaceutical Co., Ltd. (including: Hainan Simcere Pharmaceutical Co., Ltd., Nanjing Simcere Dongyuan Pharmaceutical Co., Ltd., Nanjing Dongjie Pharmaceutical Co., Ltd., Jiangsu Yanshen Biotechnology Co., Ltd.)
35 Shouguang Fukang Pharmaceutical Co., Ltd.
36 Henan Wanxi Pharmaceutical Co., Ltd.
37 Lijun Pharmaceutical (including: Shijiazhuang Siyao Co., Ltd.)
38 Shandong Lukang Pharmaceutical Co., Ltd. (including: Shandong Lukang Pharmaceutical Group Saite Co., Ltd.)
39 Jiangzhong Pharmaceutical Co., Ltd.
40 Jiangsu Jichuan Pharmaceutical Co., Ltd.
41 Shandong Luoxin Pharmaceutical Co., Ltd.
42 Jiangsu Kangyuan Group Co., Ltd. (including: Jiangsu Kangyuan Pharmaceutical Co., Ltd., Jiangsu Nanxing Pharmaceutical Co., Ltd., Lianyungang Kangbeier Medical Equipment Co., Ltd., Lianyungang Hexingtang Chinese Herbal Medicine Pieces Processing Factory)
43 Qinhuangdao Lihua Starch Co., Ltd.
p>44 Guangzhou Baiyunshan Pharmaceutical Co., Ltd. (including: Guangzhou Baiyunshan Hutchison Whampoa Traditional Chinese Medicine Co., Ltd., Guangzhou Baiyunshan Tianxin Pharmaceutical Co., Ltd., Guangzhou Baiyunshan Mingxing Pharmaceutical Co., Ltd., Guangzhou Baiyunshan Guanghua Pharmaceutical Co., Ltd. Co., Ltd., Guangzhou Baite Qiaoguang Medical Products Co., Ltd.)
45 Shandong Zibo Shanchuan Medical Equipment Co., Ltd.
46 Jiangsu Zhengda Tianqing Pharmaceutical Co., Ltd.
47 Shijiazhuang Yiling Pharmaceutical Co., Ltd.
48 Mero Pharmaceutical Co., Ltd.
49 Chengdu Diao Group
50 Anhui Fengyuan Pharmaceutical Industry Co., Ltd.
51 Zhejiang Jianfeng Pharmaceutical Co., Ltd.
52 Shandong Luye Pharmaceutical Co., Ltd.
53 Guangzhou Wanglaoji Pharmaceutical Co., Ltd.
54 Wuhan Renfu Pharmaceutical Group Co., Ltd.
55 Zhejiang Conba Pharmaceutical Co., Ltd.
56 Shandong Xianhe Pharmaceutical Co., Ltd.
57 Shandong Lukang Chenxin Pharmaceutical Co., Ltd.
58 Omron (Dalian) Co., Ltd.
59 Zhejiang Xianju Pharmaceutical Co., Ltd.
60 Jiangsu Aosaikang Pharmaceutical Co., Ltd.
61 Donggang Industry and Trade Group Co., Ltd.
62 Tiansheng Pharmaceutical Group Co., Ltd.
63 Heilongjiang Zhenbaodao Pharmaceutical Co., Ltd.
p>64 Jiangsu Suzhong Pharmaceutical Group Co., Ltd.
65 Hualan Bioengineering Co., Ltd. (including: Hualan Biological Vaccine Co., Ltd.)
66 Hangzhou Sino-American Huadong Pharmaceutical Co., Ltd.
67 Beijing Tongrentang Technology Development Co., Ltd.
68 Shanxi Weiqida Pharmaceutical Co., Ltd.
69 Shanghai Modern Pharmaceutical Co., Ltd. Companies (including: Shanghai Modern Hasen (Shangqiu) Pharmaceutical Co., Ltd.)
70 Yuekang Pharmaceutical Group Co., Ltd.
71 Guilin Sanjin Group Co., Ltd. (including: Guilin Sanjin Jin Pharmaceutical Co., Ltd., Sanjin Group Guilin Sanjin Biopharmaceutical Co., Ltd., Sanjin Group Hunan Sanjin Pharmaceutical Co., Ltd.)
72 Ningxia Qiyuan Pharmaceutical Co., Ltd.
73 Jiuzhitang Co., Ltd.
74 Shanghai Xinya Pharmaceutical Co., Ltd.
75 Jiangsu Enhua Pharmaceutical Co., Ltd.
Co., Ltd.
76 Heilongjiang Sunflower Pharmaceutical Co., Ltd.
77 Anqiu Luan Pharmaceutical Co., Ltd.
78 Heze Ruiying Pharmaceutical Group Co., Ltd.
79Beijing Fresenius Kabi Pharmaceutical Co., Ltd.
80 Guizhou Yibai Pharmaceutical Co., Ltd. (including: Guilin Yibai Lijiang Pharmaceutical Co., Ltd., Hainan Changan International Pharmaceutical Co., Ltd. )
81 Shenzhen Zhijun Pharmaceutical Co., Ltd.
82 Disha Pharmaceutical Group Co., Ltd.
83 Jiangsu Lianhuan Pharmaceutical Group Co., Ltd.
84 Jiangsu Yabang Pharmaceutical Group Co., Ltd. (including: Jiangsu Yabang Epson Pharmaceutical Co., Ltd., Jiangsu Yabang Shengyuan Pharmaceutical Co., Ltd., Jiangsu Yabang Johnson & Johnson Pharmaceutical Co., Ltd.)
85 Hengdian Group Kangyu Pharmaceutical Co., Ltd.
86 Zhengda Qingchunbao Pharmaceutical Co., Ltd.
87 Lanzhou Institute of Biological Products
88 Shandong Tianli Pharmaceutical Industry Co., Ltd.
89 Fujian Fukang Pharmaceutical Co., Ltd.
90 Sichuan Shuzhong Pharmaceutical Co., Ltd.
91 Beijing Tong Ren Tang Health Pharmaceutical Co., Ltd.
92 Astellas Pharmaceuticals (China) Co., Ltd.
93 Shanghai New Pioneer Pharmaceutical Co., Ltd.
94 Xianyang Buchang Pharmaceutical Co., Ltd.
95 Zhejiang Huahai Pharmaceutical Co., Ltd.
96 Liaoning Nuokang Biopharmaceutical Co., Ltd.
97 Beijing Tide Pharmaceutical Co., Ltd.
98 Zhejiang Hailisheng Pharmaceutical Co., Ltd.
99 Shandong Xinhua Medical Equipment Group
100 Shanghai Baite Medical Supplies Co., Ltd.
The following are industry development trends:
p>In the past year, the domestic pharmaceutical industry has seen frequent mergers of giants. The mergers between Shanghai Pharmaceutical Group Co., Ltd. (hereinafter referred to as "Shanghai Pharmaceutical Group") and Shanghai Industrial (Group) Co., Ltd. (hereinafter referred to as "SI Group") The pharmaceutical sector took the lead in merging to establish the new Shanghai Pharmaceuticals; China National Pharmaceutical Group Corporation (hereinafter referred to as "Sinopharm") was successfully reorganized on April 12 this year after merging with China National Biotec Group Corporation (hereinafter referred to as "CNBG") last year. The Shanghai Institute of Pharmaceutical Industry (hereinafter referred to as the "Institute") established New Sinopharm; just 10 days before this, China Resources Group and the Beijing Municipal People's Government officially signed the "Agreement on the Joint Development of the Pharmaceutical Industry and Microelectronics Industry" "Strategic Cooperation Framework Agreement", China Resources officially acquired Beijing Pharmaceutical and established New China Resources. At this point, with the completion of the mergers and reorganizations of the three major domestic pharmaceutical giants, the amount of M&A transactions in the pharmaceutical industry since 2009 has reached the highest peak since 2000. The competitive landscape of the pharmaceutical market has obviously changed, and the Chinese pharmaceutical industry has officially entered the Three Kingdoms era. . New Sinopharm, New China Resources, and New Shanghai Pharmaceuticals have arranged their seats. After the rearrangement, the industry leaders have emerged. The recent national requirement to form several pharmaceutical leading groups in the country has been initially realized.
New Sinopharm
The undisputed leader in China’s pharmaceutical industry is still New Sinopharm Group. On April 12, the Medical Engineering Institute was integrated into Sinopharm Group and became its wholly-owned subsidiary. The number of enterprises that the State-owned Assets Supervision and Administration Commission has performed its investor duties has been adjusted from 127 to 126. The overall merger of the Medical Engineering Institute is of great significance to Sinopharm. Although Sinopharm Group is the absolute leader in the domestic pharmaceutical industry, 80% of its profit composition comes from the pharmaceutical companies represented by Sinopharm Holdings. Even if the reorganized Sinopharm Group’s biological products continue to contribute high profits, it is still difficult to conceal the role of Sinopharm in the pharmaceutical industry. obvious shortcomings. The more pressing issue is that New Shanghai Pharmaceuticals, which was the first to be integrated, is now firmly established in East China. China Resources Group, another giant of the state-owned enterprises, has never stopped its ambition and pace of acquisitions. Driven by the new medical reform to sink the grassroots, regional leaders in various places are not to be outdone. , all formed alliances to fight against each other. Amid "domestic and foreign troubles", the Medical Engineering Institute has become a trump card that Sinopharm must win.
In the field of medical research in China, the Institute of Medical Engineering has always been a proud existence - as the only scientific research institute in the pharmaceutical industry among the central enterprises, the Institute of Medical Engineering has been affiliated to the Central Enterprise Working Committee and the State-owned Assets Supervision and Administration Commission of the State Council. Committee.
There are more than 30 listed companies in the pharmaceutical sector of the Shanghai and Shenzhen stock markets, which use their output of scientific research results as their main products. They have a target revenue of 1.5 billion yuan in 2010. Their main business is the research and development, production and sales of innovative drugs. Their R&D capabilities are second to none in the country. Although its annual operating income is less than 1 billion yuan, its strong scientific research strength has become the industrial engine and fissioner of Sinopharm Group. The two industrial enterprises under the Medical Engineering Institute, Modern Pharmaceuticals and Shanghai Modern Pharmaceutical Preparation Engineering Research Center Co., Ltd., have performed very well, and their economic and social benefits are even difficult to estimate.
On April 22, Sinopharm and Shanxi Weiqida Pharmaceutical (hereinafter referred to as "Weiqida") signed an agreement in Datong, Shanxi, and Sinopharm officially began the reorganization of Weiqida. Sinopharm Group has promised to control Weiqida through equity acquisition and capital increase. This is the first step for Sinopharm Group to launch independent mergers and acquisitions in the pharmaceutical industry. It is of great significance and can accelerate the industrialization process of Sinopharm. At the same time, after acquiring Weiqida, Sinopharm will definitely open a breakthrough in Shanxi and introduce other businesses to this area. Weiqida is the main domestic manufacturer of the medical intermediate 7-ACA, and the direct downstream product of this intermediate is ceftriaxone sodium. China is a big country in the use of anti-infective drugs. The national anti-infective drugs have grown rapidly at an average annual rate of about 17%. In 2009, the national market size of anti-infective drugs exceeded 40 billion yuan. Ceftriaxone sodium has always been the drug with the largest sales volume among antibiotics. In 2008, the Chinese Pharmaceutical Association conducted statistics on 22 hospitals across the country and found that the cost of ceftriaxone sodium reached 269.78 million yuan, far exceeding that of other drugs. CSPC Pharmaceutical Group and Fuzhou Antibiotics Group are major producers of 7-ACA, with an annual production capacity of about 1,600 tons. Weiqida ranks third, with about 1,000 tons. The annual production capacity of companies such as Joincare Yuan is less than 800 tons. In the restructuring agreement, Sinopharm stated that it will further expand Weiqida's production capacity to achieve a production scale of 1,200 tons of 7-ACA and 300 tons of clavulanic acid. It plans to achieve sales revenue of Weiqida exceeding 3 billion yuan by 2015.
As a platform for the State-owned Assets Supervision and Administration Commission to integrate central pharmaceutical enterprises, Sinopharm Group acquired Sinopharm Group on September 16, 2009, before acquiring the Medical Institute and Weiqida. With its exclusive monopoly on the vaccine business and blood products business, Sinopharm Group has become the giant King Kong of Sinopharm, which is of absolute importance to Sinopharm. Sinopharm makes up for Sinopharm's lack of blood and vaccine business. This move, part of the nearly trillion-dollar medical reform project, coincides with the State-owned Assets Supervision and Administration Commission’s long-term strategy of building Sinopharm into a large pharmaceutical group integrating trade, science and industry. Sinopharm Group has become the eighth business segment of Sinopharm Group. Previously, Sinopharm Group was China’s largest vaccine and blood product production supplier. It was mainly engaged in the manufacturing and sales of three types of biological preparations: vaccines, blood products, and diagnostic reagents. China’s 90 The planned vaccine comes from China Biotechnology Group, which had revenue of 4.9 billion yuan in 2008.
Currently, according to the vision of Song Zhiping, Chairman of Sinopharm Group, Sinopharm Group’s sales ranking will be among the top 40 by the end of 2010, and will be among the top 30 to 50 internationally competitive enterprises proposed by the central government. 30 bits. In 2009, Sinopharm Group achieved operating income of 65 billion yuan and profit of 3.63 billion yuan, ranking first in the domestic pharmaceutical industry. Among 129 central enterprises, the two indicators ranked 50th and 38th respectively. This year and next, Sinopharm has set sales revenue targets of 80 billion and 100 billion yuan respectively. Sinopharm's long-term goal is to enter the Fortune Global 500 in 2015. According to the prediction of Sinopharm Group, the entry threshold for the Fortune Global 500 will be about 160 billion yuan in terms of sales revenue.
New China Resources
China Resources Pharmaceutical Group is another card of the State-owned Assets Supervision and Administration Commission’s “building a central enterprise pharmaceutical platform”. China Resources has grown into a large pharmaceutical manufacturing and distribution enterprise based on the reorganization of the pharmaceutical resources of state-owned enterprises Huayuan Group and Sanjiu Group. China Resources Pharmaceuticals has an annual turnover of more than 27 billion yuan. It owns well-known pharmaceutical companies such as Beijing Pharmaceuticals, Sanjiu Pharmaceuticals, and China Resources Dong'e Ejiao, and directly or indirectly controls Sanjiu Pharmaceuticals, Dong'e Ejiao, Shuanghe Pharmaceuticals, Wandong Medical, etc. listed companies.
The pharmaceutical industry, together with consumer goods, electric power, and real estate, is listed as the first-level profit center of China Resources Group. China Resources has already occupied the three main markets of Shanghai, Beijing and Shenzhen in the pharmaceutical sector, and its regional layout is relatively established. Favored by the basic drug catalog introduced by the medical reform last year, Sanjiu Pharmaceutical, which has brand advantages in OTC and traditional Chinese medicine pharmaceuticals, has undoubtedly injected new vitality into China Resources. China Resources and Beiyang have officially signed the "Strategic Cooperation Framework Agreement on the Joint Development of the Pharmaceutical Industry and Microelectronics Industry" with the Beijing Municipal People's Government in Beijing on the afternoon of April 2, 2010. China Resources may be locked in increasing its stake in Beiyang. Between 5~10. The signing of the strategic agreement enabled China Resources Group to successfully complete the transformation from third to second place.
This time China Resources reorganizes Beijing Pharmaceuticals is of great significance. In December 2006, China Resources purchased 50% of Beijing Pharmacy shares held by Huayuan in cash for 2 billion yuan. After becoming the largest shareholder of Beijing Pharmacy Group, China Resources has actually not been involved in the operation and management of Beijing Pharmacy Group. In the past few years, it has further increased its holdings. This wish has not yet been clearly stated by the Beijing Municipal Government. At the same time, with the announcement of the completion of the reorganization of China National Biopharmaceutical Group and the Institute of Medical Engineering, China Resources is feeling increasing pressure. If it can no longer capture Beiyang, it will be thrown away by its opponents. At the same time, the State-owned Assets Supervision and Administration Commission has re-identified Sinopharm Group as the pharmaceutical platform of a central enterprise. China Resources is under great pressure. It hopes that through this integration, the pharmaceutical assets of its subsidiary China Resources Pharmaceutical Group will be merged with Beiyang Group, and China Resources will most likely be based on Beiyang Group. The platform of China Resources New Pharmaceutical Group has regained its position in the pharmaceutical industry of state-owned enterprises. After the reorganization of Beiyang, the pharmaceutical assets controlled by China Resources will include Beiyang, China Resources Sanjiu, and Dong'e Ejiao, covering the fields of traditional Chinese medicine, health products, pharmaceutical distribution, and medical devices. Not only can China Resources build a new China Resources Pharmaceutical Group platform based on Beijing Pharmaceutical Group, but it can also form a pharmaceutical pattern of "Beiyang at the top" and "Sanjiu at the bottom". The overall scale will also surpass the new Shanghai Pharmaceuticals and rank first in the country. Second place. Beiyang's sales revenue in 2009 was 26.9 billion yuan, ranking third among Chinese pharmaceutical companies. With the acquisition of Beiyang, China Resources Pharmaceutical's revenue in 2009 will increase to 33.7 billion yuan, surpassing New Drug and ranking second in the country in terms of scale.
New Shanghai Pharmaceuticals
Although New Shanghai Pharmaceuticals Group has fallen to the third place in the industry, its efforts to consolidate and strengthen its strength began very early. In October 2009, Shanghai Pharmaceuticals, a subsidiary of Shanghai Pharmaceuticals Group, integrated the pharmaceutical assets of SI Group and Shanghai Pharmaceuticals Group through mergers and acquisitions and the issuance of shares to purchase assets. A new Shanghai Pharmaceuticals emerged and became a pharmaceutical subsidiary of Shanghai State-owned Assets. Industrial resource integration platform. At the beginning of 2010, New Shanghai Pharmaceuticals acquired four foreign pharmaceutical companies in one go and signed acquisition framework agreements with three companies, Guangzhou Zhongshan Pharmaceutical Co., Ltd., Shandong Shanglian Biochemical Pharmaceutical Co., Ltd. and Changzhou Yabang Pharmaceutical.
In 2009, the total assets of Sinopharm jumped from 8 billion yuan to 22.3 billion yuan, the sales revenue jumped from 23 billion yuan to 30 billion yuan, and the net profit was 880 million yuan, making it second only to Sinopharm at that time. The second largest pharmaceutical group in China, the Group has now been left behind by China Resources. Although it does not belong to the category of central enterprises, the pharmaceutical commercial sales scale of the reorganized new Shanghai Pharmaceuticals Group has firmly ranked first in East China. Shanghai Pharmaceuticals’ plan is to achieve revenue of 50 billion yuan in 2012, more than 35 varieties with over 100 million yuan in 2013, and revenue of 80 billion yuan in 2015